-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head-To-Head Comparison: OLO (NYSE:OLO) and Protagenic Therapeutics (OTCMKTS:PTIX)
Head-To-Head Comparison: OLO (NYSE:OLO) and Protagenic Therapeutics (OTCMKTS:PTIX)
OLO (NYSE:OLO – Get Rating) and Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
Insider and Institutional Ownership
80.4% of OLO shares are owned by institutional investors. Comparatively, 3.5% of Protagenic Therapeutics shares are owned by institutional investors. 40.5% of OLO shares are owned by insiders. Comparatively, 45.0% of Protagenic Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Get OLO alerts:Profitability
This table compares OLO and Protagenic Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
OLO | -22.06% | -3.99% | -3.62% |
Protagenic Therapeutics | N/A | -40.74% | -36.58% |
Risk and Volatility
OLO has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500.Earnings & Valuation
This table compares OLO and Protagenic Therapeutics' top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
OLO | $149.37 million | 8.32 | -$42.27 million | ($0.23) | -33.96 |
Protagenic Therapeutics | N/A | N/A | -$4.52 million | N/A | N/A |
Protagenic Therapeutics has lower revenue, but higher earnings than OLO.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for OLO and Protagenic Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
OLO | 0 | 2 | 2 | 0 | 2.50 |
Protagenic Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
OLO currently has a consensus price target of $13.40, suggesting a potential upside of 71.57%. Protagenic Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 419.48%. Given Protagenic Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protagenic Therapeutics is more favorable than OLO.
Summary
OLO beats Protagenic Therapeutics on 6 of the 11 factors compared between the two stocks.
About OLO
(Get Rating)
Olo Inc. provides software-as-a-service platform for multi-location restaurants in the United States. The company's platform enables on-demand commerce operations, which cover digital ordering and delivery through online and mobile ordering modules. Its modules include Order Management, an on-demand digital commerce and channel management solutions that enables consumers to order directly from and pay restaurants via mobile, web, kiosk, voice, and other digital channels; and Delivery Enablement, a fulfillment network, as well as a network aggregator and channel management solution, which enables restaurants to offer, manage, and expand direct delivery, as well as allows restaurants to control and syndicate menu, pricing, location data, and availability, while directly integrating and optimizing orders from third-parties into the restaurants' point-of-sale and systems. The company also provides Customer Engagement solution, a suite of restaurant-centric marketing and sentiment solutions that enables restaurants to collect, analyze, and act on guest data; Front-of-House solution, which enables restaurants to streamline the queue orders from multiple sales channels; and Payment solution, a payment platform that offers fraud prevention that results in enhanced authorization rates for valid transactions. The company was formerly known as Mobo Systems, Inc. and changed its name to Olo Inc. in January 2020. Olo Inc. was incorporated in 2005 and is headquartered in New York, New York.
About Protagenic Therapeutics
(Get Rating)
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Receive News & Ratings for OLO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OLO and related companies with MarketBeat.com's FREE daily email newsletter.
OLO (NYSE:OLO – Get Rating) and Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
OLO(NYSE:OLO-GET Rating)和Protag Treateutics(OTCMKTS:PTIX-GET Rating)都是小盘计算机和科技公司,但哪种投资更好?我们将根据这两家公司的收益、风险、估值、股息、分析师建议、机构所有权和盈利能力来比较它们的实力。
Insider and Institutional Ownership
内部人与机构持股
80.4% of OLO shares are owned by institutional investors. Comparatively, 3.5% of Protagenic Therapeutics shares are owned by institutional investors. 40.5% of OLO shares are owned by insiders. Comparatively, 45.0% of Protagenic Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
80.4%的OLO股份由机构投资者持有。相比之下,Protag Treateutics 3.5%的股份由机构投资者持有。40.5%的OLO股份由内部人士持有。相比之下,普罗泰根治疗公司45.0%的股份由内部人士持有。强大的机构持股表明,捐赠基金、对冲基金和大型基金管理公司相信,一家公司有望实现长期增长。
Profitability
盈利能力
This table compares OLO and Protagenic Therapeutics' net margins, return on equity and return on assets.
该表比较了OLO和Protag Treeutics的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
OLO | -22.06% | -3.99% | -3.62% |
Protagenic Therapeutics | N/A | -40.74% | -36.58% |
净利润率 | 股本回报率 | 资产回报率 | |
日志 | -22.06% | -3.99% | -3.62% |
孕激素治疗学 | 不适用 | -40.74% | -36.58% |
Risk and Volatility
风险和波动性
Earnings & Valuation
收益与估值
This table compares OLO and Protagenic Therapeutics' top-line revenue, earnings per share and valuation.
此表比较了OLO和Protag Treateutics的营收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
OLO | $149.37 million | 8.32 | -$42.27 million | ($0.23) | -33.96 |
Protagenic Therapeutics | N/A | N/A | -$4.52 million | N/A | N/A |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
日志 | 1.4937亿美元 | 8.32 | -4,227万元 | ($0.23) | -33.96 |
孕激素治疗学 | 不适用 | 不适用 | -452万美元 | 不适用 | 不适用 |
Protagenic Therapeutics has lower revenue, but higher earnings than OLO.
普罗吉治疗公司的收入低于OLO,但收益高于OLO。
Analyst Ratings
分析师评级
This is a breakdown of current ratings and recommmendations for OLO and Protagenic Therapeutics, as reported by MarketBeat.com.
据MarketBeat.com报道,这是对OLO和Protag Treeutics的当前评级和推荐的细分。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
OLO | 0 | 2 | 2 | 0 | 2.50 |
Protagenic Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
日志 | 0 | 2 | 2 | 0 | 2.50 |
孕激素治疗学 | 0 | 0 | 1 | 0 | 3.00 |
OLO currently has a consensus price target of $13.40, suggesting a potential upside of 71.57%. Protagenic Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 419.48%. Given Protagenic Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protagenic Therapeutics is more favorable than OLO.
Olo目前的普遍目标价为13.40美元,暗示潜在上行空间为71.57%。普罗吉治疗公司的共识目标价为4.00美元,这意味着潜在的上涨419.48%。鉴于普罗吉治疗公司更高的共识评级和更高的可能上行空间,分析人士显然认为普罗塔吉治疗公司比OLO更有利。
Summary
摘要
OLO beats Protagenic Therapeutics on 6 of the 11 factors compared between the two stocks.
在两只股票之间的11个因素中,OLO在6个因素上击败了普罗吉治疗公司。
About OLO
关于OLO
(Get Rating)
(获取评级)
Olo Inc. provides software-as-a-service platform for multi-location restaurants in the United States. The company's platform enables on-demand commerce operations, which cover digital ordering and delivery through online and mobile ordering modules. Its modules include Order Management, an on-demand digital commerce and channel management solutions that enables consumers to order directly from and pay restaurants via mobile, web, kiosk, voice, and other digital channels; and Delivery Enablement, a fulfillment network, as well as a network aggregator and channel management solution, which enables restaurants to offer, manage, and expand direct delivery, as well as allows restaurants to control and syndicate menu, pricing, location data, and availability, while directly integrating and optimizing orders from third-parties into the restaurants' point-of-sale and systems. The company also provides Customer Engagement solution, a suite of restaurant-centric marketing and sentiment solutions that enables restaurants to collect, analyze, and act on guest data; Front-of-House solution, which enables restaurants to streamline the queue orders from multiple sales channels; and Payment solution, a payment platform that offers fraud prevention that results in enhanced authorization rates for valid transactions. The company was formerly known as Mobo Systems, Inc. and changed its name to Olo Inc. in January 2020. Olo Inc. was incorporated in 2005 and is headquartered in New York, New York.
Olo Inc.为美国的多家餐厅提供软件即服务平台。该公司的平台支持按需商务运营,其中包括数字订购和通过在线和移动订购模块交付。它的模块包括Order Management,一种按需数字商务和渠道管理解决方案,使消费者能够通过移动、网络、售货亭、语音和其他数字渠道直接从餐厅订购并支付;Delivery Enablement,一种履行网络,以及网络聚合器和渠道管理解决方案,使餐厅能够提供、管理和扩大直接送货,并允许餐厅控制和辛迪加菜单、定价、位置数据和可用性,同时将来自第三方的订单直接集成和优化到餐厅的销售点和系统中。该公司还提供客户参与解决方案,这是一套以餐厅为中心的营销和情绪解决方案,使餐厅能够收集、分析客人数据并采取行动;前置解决方案,使餐厅能够简化来自多个销售渠道的排队订单;以及支付解决方案,提供防欺诈功能,从而提高有效交易的授权率。该公司前身为Mobo Systems,Inc.,于2020年1月更名为Olo Inc.。Olo Inc.成立于2005年,总部设在纽约。
About Protagenic Therapeutics
关于前列腺素治疗学
(Get Rating)
(获取评级)
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
前列基因治疗公司是一家生物制药公司,致力于发现和开发治疗与压力相关的神经精神和情绪障碍的疗法。它的先导化合物是PT00114,这是Teneurin羧基末端相关肽的合成形式,Teneurin羧基末端相关肽是一种内源性大脑信号肽,可以抑制过度活跃的应激反应。该公司总部设在纽约,纽约州。
Receive News & Ratings for OLO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OLO and related companies with MarketBeat.com's FREE daily email newsletter.
接收OLO日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对OLO和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧